1 unchanged sentence
(c) Trading Plans
−Removed: During the quarter ended June 30, 2025, no director or officer (as defined in Exchange Act Rule 16a-1(f)) adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement.
+Added: During the quarter ended December 31, 2025, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):
+Added: Name Title Adoption or Termination Date Plan End Date Shares Vesting and Subject to Sell-To-Cover (1)
+Added: Other Shares Being Sold (Subject to Certain Conditions)
+Added: Christopher Anzalone President and Chief Executive Officer 12/22/2025 01/31/2030 1,871,805 n/a
+Added: James Hamilton Chief Medical Officer, Head of R&D 12/02/2025 03/05/2027 n/a 44,000
+Added: (1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.
Number Document Description
2 unchanged sentences
(incorporated by reference from Exhibit 3.2 of the Company’s Form 10-Q filed on May 2, 2023)
−Removed: Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023 (incorporated by reference from Exhibit 3.3 of the Company’s Form 10-Q filed on May 2, 2023)
−Removed: Severance and Change of Control Agreement by and between Company and Christopher Anzalone, dated May 9, 2025 (incorporated by reference from Exhibit 10.1 of the Company’s Form 10-Q filed on May 12, 2025)
−Removed: Severance and Change of Control Agreement by and between Company and Daniel Apel, dated May 8, 2025 (incorporated by reference from Exhibit 10.
−Removed: 2 of the Company’s Form 10-Q filed on May 12, 2025)
−Removed: Severance and Change of Control Agreement by and between Company and Patrick O'Brien, dated May 9, 2025 (incorporated by reference from Exhibit 10.
−Removed: 3 of the Company’s Form 10-Q filed on May 12, 2025)
−Removed: Severance and Change of Control Agreement by and between Company and James Hamilton, dated May 8, 2025 (incorporated by reference from Exhibit 10.
−Removed: 4 of the Company’s Form 10-Q filed on May 12, 2025)
−Removed: CFO Retirement Letter by and between Company and Ken Myszkowski, dated May 9, 2025 (incorporated by reference from Exhibit 10.
−Removed: 5 of the Company’s Form 10-Q filed on May 12, 2025)
−Removed: Amendment No.
−Removed: 1 2 to Lease Agreement by and between Arrowhead Madison, Inc.
−Removed: and University Research Park, dated June 1 1 , 202 5
+Added: 3.3* Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023
+Added: A mendment No.
+Added: 2 to Financing Agreement between Arrowhead Pharmaceuticals, Inc.
+Added: and Sixth Street Lending Partners dated August 7, 2024
31.1* Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
16 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: August 7, 2025
+Added: February 5, 2026
ARROWHEAD PHARMACEUTICALS, INC.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.